Literature DB >> 12741474

Prevalence of transaminase abnormalities in asymptomatic, healthy subjects participating in an executive health-screening program.

Cary H Patt1, Hwan Y Yoo, Kourosh Dibadj, John Flynn, Paul J Thuluvath.   

Abstract

The objective of this study was to characterize the prevalence of asymptomatic liver transminase (LT) abnormalities in a healthy, low-risk adult population and identify associated risk factors. We reviewed 2340 completed medical records of participants in our Executive Health Program, which provided screening medical evaluations for executives. LT (alanine aminotransferase and aspartate aminotransferase) were considered abnormal if they above normal range for our laboratory. Subjects were excluded if they had a history of viral hepatitis, nonviral liver disease, or an identifiable cause of LT elevation. Of the 2340 subjects 2294 met inclusion criteria and all had AST recorded, but only 1309 had ALT recorded. In all, 341 subjects (14.9%) were found to have abnormal LT and in those who had less than 3 drinks per day, 13.9% had elevated LT and 3.6% had LT twice the upper limit of normal. Of the 1309 subjects in whom both AST and ALT were measured, 20.8% had abnormal LT and 6.3% had LT twice the upper limit of normal. On univariate analysis age < 60 (P = 0.005), male sex (P < 0.0001), body mass index > or = 30 (P < 0.0001), cholesterol > or = 200 mg/dl (P = 0.018), and triglycerides > or = 200 mg/dl (P < 0.0001) were associated with abnormal LT; all these variables except cholesterol were significant by logistic regression analysis. The odds ratio of abnormal LT and LT 2 times normal was 1.79 (CI 1.20-2.68) and 2.50 (CI 1.04-6), respectively, in subjects with one risk factor, and 2.80 (CI 1.07-7.34) and 4.73 (CI 0.91-24.5), respectively, in subjects with four risk factors. In conclusion, there is a high prevalence of LT abnormalities in this healthy population. Subjects with multiple risk factors should be considered for screening.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12741474     DOI: 10.1023/a:1022809430756

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  20 in total

Review 1.  Evaluation of abnormal liver-enzyme results in asymptomatic patients.

Authors:  D S Pratt; M M Kaplan
Journal:  N Engl J Med       Date:  2000-04-27       Impact factor: 91.245

2.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.

Authors:  J B Dixon; P S Bhathal; P E O'Brien
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

3.  NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome.

Authors:  Shivakumar Chitturi; Shehan Abeygunasekera; Geoffrey C Farrell; Jane Holmes-Walker; Jason M Hui; Caroline Fung; Rooshdiya Karim; Rita Lin; Dev Samarasinghe; Christopher Liddle; Martin Weltman; Jacob George
Journal:  Hepatology       Date:  2002-02       Impact factor: 17.425

Review 4.  Nonalcoholic steatohepatitis.

Authors:  A M Diehl
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

Review 5.  Nonalcoholic steatohepatitis.

Authors:  A E Reid
Journal:  Gastroenterology       Date:  2001-09       Impact factor: 22.682

6.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.

Authors:  C A Matteoni; Z M Younossi; T Gramlich; N Boparai; Y C Liu; A J McCullough
Journal:  Gastroenterology       Date:  1999-06       Impact factor: 22.682

7.  Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients.

Authors:  S Daniel; T Ben-Menachem; G Vasudevan; C K Ma; M Blumenkehl
Journal:  Am J Gastroenterol       Date:  1999-10       Impact factor: 10.864

8.  Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study.

Authors:  A Poonawala; S P Nair; P J Thuluvath
Journal:  Hepatology       Date:  2000-10       Impact factor: 17.425

9.  Nonalcoholic steatohepatitis: an expanded clinical entity.

Authors:  B R Bacon; M J Farahvash; C G Janney; B A Neuschwander-Tetri
Journal:  Gastroenterology       Date:  1994-10       Impact factor: 22.682

10.  The natural history of nonalcoholic fatty liver: a follow-up study.

Authors:  M R Teli; O F James; A D Burt; M K Bennett; C P Day
Journal:  Hepatology       Date:  1995-12       Impact factor: 17.425

View more
  11 in total

1.  Nonalcoholic fatty liver disease (NAFLD) in the Veterans Administration population: development and validation of an algorithm for NAFLD using automated data.

Authors:  N Husain; P Blais; J Kramer; M Kowalkowski; P Richardson; H B El-Serag; F Kanwal
Journal:  Aliment Pharmacol Ther       Date:  2014-08-26       Impact factor: 8.171

2.  A better parameter in predicting insulin resistance: obesity plus elevated alanine aminotransferase.

Authors:  Ping-Hao Chen; Jong-Dar Chen; Yu-Cheng Lin
Journal:  World J Gastroenterol       Date:  2009-11-28       Impact factor: 5.742

3.  Management of liver cirrhosis between primary care and specialists.

Authors:  Ignazio Grattagliano; Enzo Ubaldi; Leonilde Bonfrate; Piero Portincasa
Journal:  World J Gastroenterol       Date:  2011-05-14       Impact factor: 5.742

Review 4.  Can NASH be diagnosed, graded, and staged noninvasively?

Authors:  Garfield A Grandison; Paul Angulo
Journal:  Clin Liver Dis       Date:  2012-06-26       Impact factor: 6.126

Review 5.  Non-alcoholic fatty liver disease: what the clinician needs to know.

Authors:  Mariana Verdelho Machado; Helena Cortez-Pinto
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

6.  Serum levels of alanine aminotransferase decrease with age in longitudinal analysis.

Authors:  Mamie H Dong; Ricki Bettencourt; David A Brenner; Elizabeth Barrett-Connor; Rohit Loomba
Journal:  Clin Gastroenterol Hepatol       Date:  2011-10-20       Impact factor: 11.382

7.  Reasons for ordering laboratory tests and relationship with frequency of abnormal results.

Authors:  Paul H H Houben; Ron A G Winkens; Trudy van der Weijden; Renee C R M Vossen; André J M Naus; Richard P T M Grol
Journal:  Scand J Prim Health Care       Date:  2010-03       Impact factor: 2.581

Review 8.  Endocrine causes of nonalcoholic fatty liver disease.

Authors:  Laura Marino; François R Jornayvaz
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

9.  Alanine aminotransferase decreases with age: the Rancho Bernardo Study.

Authors:  Mamie H Dong; Ricki Bettencourt; Elizabeth Barrett-Connor; Rohit Loomba
Journal:  PLoS One       Date:  2010-12-08       Impact factor: 3.240

10.  A diagnostic model for cirrhosis in patients with non-alcoholic fatty liver disease: an artificial neural network approach.

Authors:  Omid Pournik; Sara Dorri; Hedieh Zabolinezhad; Seyyed Moayed Alavian; Saeid Eslami
Journal:  Med J Islam Repub Iran       Date:  2014-10-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.